Check Cap (CHEK) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of Check Cap (NASDAQ:CHEK) from a sell rating to a hold rating in a report issued on Wednesday morning.

CHEK has been the subject of a number of other reports. Zacks Investment Research upgraded Check Cap from a hold rating to a buy rating and set a $1.00 target price for the company in a research note on Monday, January 15th. HC Wainwright started coverage on Check Cap in a research note on Tuesday, March 13th. They issued a buy rating and a $6.00 target price for the company.

How to Become a New Pot Stock Millionaire

NASDAQ:CHEK opened at $3.59 on Wednesday. Check Cap has a one year low of $3.58 and a one year high of $27.60.

Check Cap (NASDAQ:CHEK) last posted its quarterly earnings results on Wednesday, April 4th. The medical research company reported ($1.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($1.07). equities analysts predict that Check Cap will post -6.48 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Check Cap stock. Anson Funds Management LP bought a new stake in Check Cap Ltd (NASDAQ:CHEK) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 332,302 shares of the medical research company’s stock, valued at approximately $289,000. Anson Funds Management LP owned 1.73% of Check Cap as of its most recent SEC filing. 22.18% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Check Cap (CHEK) Raised to “Hold” at ValuEngine” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/check-cap-chek-raised-to-hold-at-valuengine.html.

About Check Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply